Insights into Hepatocellular Carcinoma (HCC) 2020 (Northeast)
Current treatment practice attitudes toward therapy of unresectable advanced hepatocellular carcinoma (HCC), recently introduced and upcoming agents
Northeast – August 19, 2020
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center, Scottsdale, AZ, USA
REPORT SNAPSHOT
- A roundtable discussion, moderated by an Axess Oncology Network physician, focusing on the treatment of HCC was held on August 19, 2020, in a virtual setting
- Disease state and data presentations were developed in conjunction with Dr Tanios Bekaii-Saab from Mayo Clinic Cancer Center
- The group of advisors comprised community oncologists from the Northeast region of the United States
- Insights on the following therapies were obtained: sorafenib, lenvatinib, cabozantinib, bevacizumab, atezolizumab, pembrolizumab, ramucirumab, ipilimumab, and nivolumab
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection was accomplished through use of audience response system questioning and moderated discussion
- Attendees of the roundtable represented community oncologists from New Jersey, Massachusetts, Maryland, Vermont, and Pennsylvania
